Connect with us

Technology

New Survey Shows Strong Patient Support for Personalized Obesity Interventions

Published

on

Respondents ages 18 to 65 highlight urgency for medical recognition, scientifically proven interventions, and genetic testing for personalized obesity treatment.

MENLO PARK, Calif., Aug. 1, 2024 /PRNewswire/ — Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, today announces the results from a new U.S. weight loss survey from 475 patients who have struggled with excess weight or are currently overweight or obese. The survey provides valuable insights into patients’ evolving preferences for obesity treatment, how they receive this information, and what that means for the future of anti-obesity medications, like GLP-1s.

The survey findings reveal the majority of patients are interested in treating obesity as a medical condition. Two-thirds (66 percent) of patients surveyed prefer guidance from clinical care providers to manage their weight loss. The survey also highlights patients’ growing desire to personalize obesity care to their specific needs. Nearly two-thirds of patients surveyed (62 percent) are interested in learning more about their condition through genetic testing and want an obesity intervention tailored to their genetic findings. This data indicates strong momentum for personalized medicine as a cornerstone in the treatment of obesity. In addition, 53 percent of them are willing to pay for a genetic obesity test.

“Getting expert clinical advice on managing weight loss, as opposed to information readily consumed on social media platforms, is vital for patients’ ongoing success in their weight loss journey,” said Zaid Jabbar, M.D., M.S., obesity medicine physician with Duly Health and Care. “This survey shows that patients are more likely than ever to talk with their provider about taking control of their weight loss, and we know that involving a healthcare provider improves treatment adherence significantly. By offering the MyPhenome test in our clinic, we believe we can now offer better care and positively impact patients’ perspectives on their weight loss journey, ultimately changing the conversation with our patients for the better.”

While the patient perspective is shifting to a more clinical mindset surrounding obesity care, respondents largely noted they first learned about GLP-1s and weight loss medications via TV (36 percent) and social media, including TikTok (28 percent), Instagram/Facebook (26 percent) and Twitter/X (20 percent). This is in contrast to just 17 percent hearing about it from a healthcare provider, showcasing a continued need for patient education and communication surrounding clinical weight loss solutions backed by scientific evidence.

“The results of this survey reflect a notable evolution for obesity treatment. The new obesity medications have reinforced the long overdue need to treat obesity as a disease and it’s clear patients welcome that change. However, as this transition continues, it is clear, too, that there needs to be more focus on how patients receive weight loss information and utilize available treatments backed by scientific research,” says Mark Bagnall, CEO of Phenomix Sciences.

“We’ve seen that there is no ‘one-size-fits all’ solution, even with new and effective medications, and the average patient with obesity is now expressing a growing curiosity about the root causes of obesity. Our goal is to reach patients where they are, whether that’s providing the MyPhenomeTM test to obesity medicine providers in local markets and clinics or through telehealth platforms like Hello Alpha. These partnerships not only enhance patient outcomes but also contribute substantially to addressing and mitigating the global epidemic of obesity,” Bagnall said.

For more information about Phenomix Sciences, visit phenomixsciences.com.

About Phenomix Sciences
Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer obesity globally through the use of our proprietary genetic tests, unique data sets and advanced analytics. Phenomix believes that the key to understanding obesity is its unprecedented access to clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence to yield better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients. For more information, please visit www.phenomixsciences.com.

Media Contact:
phenomix@ampublicrelations.com

View original content:https://www.prnewswire.com/news-releases/new-survey-shows-strong-patient-support-for-personalized-obesity-interventions-302212282.html

SOURCE Phenomix Sciences

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ZNShine Solar Powers Honduras’ Renewable Future with 50MW Patuca Solar Project

Published

on

By

TERRERO BLANCO, Honduras, March 26, 2025 /PRNewswire/ — ZNShine Solar, a global leader in photovoltaic technology, today announced its role as module supplier for the 50MW Patuca Solar Project in Honduras. The project, developed by Empresa Nacional de Energía Eléctrica de Honduras (ENEE) and used Representaciones Mecánico Eléctricas, S.A. (REMESA) as EPC, represents a significant step in the country’s clean energy transition.

Financed through non-recourse debt by the Central Bank Honduras in December 2024, the project utilizes ZNShine’s high-efficiency 12BB PERC Monofacial Double-Glass Modules, selected for their:

Superior durability in harsh weather conditionsEnhanced energy yield for optimal performanceProven wind resistance, ideal for large-scale installations

Scheduled for commissioning in October 2025, the installation will significantly expand Honduras’ renewable energy capacity while supporting national energy security goals.

“Projects like Patuca demonstrate how advanced solar technology can drive sustainable development,” said William Wang, CEO at ZNShine Solar. “Our modules deliver the reliability and efficiency needed for Honduras’ energy future.”

About ZNShine Solar
A BNEF Tier 1 manufacturer and PVEL Top Performer, ZNShine Solar (founded 2006) delivers high-performance PV modules and integrated solutions across 60+ countries. With 10GW+ global capacity and manufacturing bases in China and internationally, the company is recognized for technological innovation in the Global Top 500 New Energy Enterprises.

View original content to download multimedia:https://www.prnewswire.com/news-releases/znshine-solar-powers-honduras-renewable-future-with-50mw-patuca-solar-project-302411874.html

SOURCE ZNSHINE

Continue Reading

Technology

Patent Index 2024: US Innovation Remains Strong Despite Global Economic Uncertainties

Published

on

By

U.S. ranks first in European patent applications, followed by Germany, Japan, China, and Republic of Korea European Patent Office (EPO) received nearly 200,000 patent applications last year, with U.S. companies and inventors contributing nearly a quarter of thoseKey sectors for the U.S.: Medical technology, computer technology and digital

MUNICH and NEW YORK, March 25, 2025 /PRNewswire/ — Companies and inventors from around the world filed 199,264 patent applications at the European Patent Office (EPO) last year, according to the Patent Index 2024 published today. The U.S. maintained its position as the top country of origin for European patent applications, followed by Germany, Japan, China, and the Republic of Korea. U.S. innovators filed 47,787 applications, accounting for 24% of the total at the EPO in 2024.

Overall, the high level of patenting activity at the EPO was on a par with the previous year (2023: 199 452, -0.1%), following three years of significant growth. Patent applications from Europe, including all 39 EPO member states, rose by 0.3%, while those from outside Europe fell slightly (-0.4%). Notably, R. Korea saw the strongest growth (+4.2%), China’s growth slowed to +0.5%, while companies and inventors from the U.S. (-0.8%) and Japan (-2.4%) filed fewer applications.    

“Despite global uncertainties, U.S. companies and inventors continue to invest in research and development,” said EPO President António Campinos. “The rapid rise of digital technologies and AI is spurring innovation across all sectors. In 2024, the U.S. was one of the main drivers in advancing computer technology to the top technology field at the EPO. This underscores Europe’s significance as a key technology market for U.S. companies, offering a high-quality patent system that supports the development of strong IP portfolios.”

U.S. Top Fields of Technology: Surge in Computers, led by AI
The leading fields of technology for U.S. applicants at the EPO reflect significant strengths in various high-growth industries. The top three in 2024 were:

Medical technology: top field with 5,995 applications, reflecting continued investment in healthcare innovation, although it experienced a slight decrease of 2.9% compared to 2023.Computer technology: with 5,776 applications, this field saw a significant increase of +11.4% from the U.S. Growth from the U.S. was even higher (+20%) in AI-related fields such as machine learning and pattern recognition.Digital communication: which includes inventions related to mobile networks, accounted for 4,628 applications, but experienced a decrease of 4.8%.

U.S. Tech Companies Lead Innovation Push
Out of all global applicants, six of the top 20 businesses with most applications at the EPO are U.S.-based. They include: semiconductor manufacturer Qualcomm (with 3,015 patent applications, ranking 4th globally), aerospace and defence company RTX (2,061 applications), Alphabet (1,171), Microsoft (1,131), InterDigital (863), and Apple (806).

Samsung back at No. 1 in EPO Applicant Ranking
Samsung was the leading filer of patent applications at the EPO overall in 2024 (having last topped the ranking in 2020), Huawei dropped to second, followed by LG, Qualcomm and RTX.

Further information

View the Patent Index 2024 in full

 

View original content:https://www.prnewswire.com/news-releases/patent-index-2024-us-innovation-remains-strong-despite-global-economic-uncertainties-302411878.html

SOURCE European Patent Office (EPO)

Continue Reading

Technology

Canaan Inc. Expands Self-Mining Footprint in North America

Published

on

By

New mining partnerships to add ~4.7 EH/s

Mining machines to be hosted at facilities in Pennsylvania and Texas

Self-mining energization expected in coming months

SINGAPORE, March 26, 2025 /PRNewswire/ — Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), an innovator in crypto mining, today announced that wholly owned subsidiaries of Canaan have signed agreements that expand the Company’s self-mining capabilities at two new partners’ mining facilities in Pennsylvania and Texas.

A three-year master colocation agreement has been entered into with Mawson Hosting LLC, an affiliate of Mawson Infrastructure Group Inc. (NASDAQ: MIGI), for its facility in Midland, Pennsylvania. This expansion in Pennsylvania, together with another recently executed 24-month equipment hosting agreement for a facility in Edna, Texas, is expected to add around 4.7EH/s of North American hashrate to Canaan’s self-mining computing power. The majority of this hashrate is expected to be installed by the second quarter of 2025.

“Our team has been evaluating mining sites across North America for several months, patiently looking for self-mining and partnership opportunities that made sense for our business.  We believe that these two new partners have goals that align with Canaan’s and that we can build long-term relationships with them,” said Nangeng Zhang, chairman and chief executive officer of Canaan.  “The U.S. has regulatory policies that support our Company’s ambitions, and we believe that we will be able to find additional partnerships and sites that will help us to increase our presence in the U.S. through self-mining activities and provide us with additional opportunities for mining machine sales.”

“We are delighted to announce the partnership between Canaan and Mawson. This agreement aligns with our strategy of optimizing digital infrastructure and compute management capabilities with the latest-generation machines. By combining Canaan’s cutting-edge hardware and Mawson’s digital infrastructure innovation, we expect to create long-term value that will benefit both companies as well as the overall ecosystem,” said Rahul Mewawalla, chief executive officer and president of Mawson Infrastructure Group Inc.

About Canaan Inc.

Established in 2013, Canaan Inc. (NASDAQ: CAN), is a technology company focusing on ASIC high-performance computing chip design, chip research and development, computing equipment production, and software services. Canaan has extensive experience in chip design and streamlined production in the ASIC field. In 2013, Canaan’s founding team shipped to its customers the world’s first batch of mining machines incorporating ASIC technology in bitcoin‘s history under the brand name Avalon. In 2019, Canaan completed its initial public offering on the Nasdaq Global Market. To learn more about Canaan, please visit https://www.canaan.io/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, Canaan Inc.’s anticipated financing plans and its intended use of proceeds contain forward-looking statements. Canaan Inc. may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”) on Forms 20-F and 6-K, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Canaan Inc.’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition and results of operations; the expected growth of the bitcoin industry and the price of bitcoin; the Company’s expectations regarding demand for and market acceptance of its products, especially its bitcoin mining machines; the Company’s expectations regarding maintaining and strengthening its relationships with production partners and customers; the Company’s investment plans and strategies, fluctuations in the Company’s quarterly operating results; competition in its industry; and relevant government policies and regulations relating to the Company and cryptocurrency. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Canaan Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact

Canaan Inc.
Xi Zhang
Email: IR@canaan-creative.com 

ICR, LLC.
Robin Yang
Tel: +1 (347) 396-3281
Email: canaan.ir@icrinc.com 

View original content:https://www.prnewswire.com/news-releases/canaan-inc-expands-self-mining-footprint-in-north-america-302411876.html

SOURCE Canaan Inc.

Continue Reading

Trending